Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 17-22, 2026, in San Diego, California.

A focus of this year's data is the introduction of a new NeXT Personal MRD test option, Real-Time Variant Tracker, a first-of-its-kind feature in tumor-informed clinical MRD testing, designed to longitudinally track therapy resistance mutations.

"We are thrilled to present the first NeXT Personal data on the Real-Time Variant Tracker. The AACR data highlights how tracking therapy resistance mutations like ESR1 during MRD testing has the potential to inform patient management once cancer recurrence is detected," said Dr. Richard Chen, President and Chief Medical Officer at Personalis. "In addition, the data presented at AACR further reinforces that ultrasensitive ctDNA detection with NeXT Personal can impact how colorectal cancer is monitored and managed. Both of these studies are examples of our unwavering commitment to innovation to drive better outcomes for patients."

Presentations at AACR highlighting the use and clinical impact of the ultrasensitive NeXT Personal MRD test include:

Oral Podium Presentation: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction.

Focus: Highlights the ultrasensitive ctDNA detection of NeXT Personal for predicting and tracking response to neoadjuvant immunotherapy in CRC patients.

Time: April 20, 2026, 2:35 PM–2:45 PM

Location: Room Hall H - Ground Level

Poster Presentation: Monitoring ESR1 and other mutations linked to resistance with a tumor-informed MRD test: Analytical validation and real world data.

Focus: Presents the analytical validation and real-world case studies of the new Real-Time Variant Tracker feature of NeXT Personal enabling detection of resistance and other clinical mutations during MRD testing.

Time: April 20, 2026, 9:00 AM–12:00 PM

Location: Section 46, Poster #2588

Poster Presentation: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data.

Focus: A deep analysis of the real-world clinical performance of NeXT Personal across a large patient cohort. The data highlights the ability for NeXT Personal to consistently achieve ultrasensitive ctDNA detection levels below 100 parts per million (ppm) and 10 ppm, across a diverse set of solid tumor types, stages, and challenging real-world testing conditions.

Time: April 20, 2026, 2:00 PM–5:00 PM

Location: Section 45, Poster #8225

Poster Presentation: Ultrasensitive ctDNA monitoring predicts early response of immunotherapy in recurrent metastatic non-small cell lung cancer.

Focus: Demonstrates the performance of NeXT Personal for predicting relapse and outcomes in advanced NSCLC patients receiving immunotherapy.

Time: April 20, 2026, 2:00 PM–5:00 PM

Location: Section 45, Poster #3851